205 related articles for article (PubMed ID: 11030470)
1. Nateglinide.
Dunn CJ; Faulds D
Drugs; 2000 Sep; 60(3):607-615; discussion 616-7. PubMed ID: 11030470
[TBL] [Abstract][Full Text] [Related]
2. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent.
McLeod JF
Clin Pharmacokinet; 2004; 43(2):97-120. PubMed ID: 14748619
[TBL] [Abstract][Full Text] [Related]
5. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
Kalbag JB; Walter YH; Nedelman JR; McLeod JF
Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus.
Keilson L; Mather S; Walter YH; Subramanian S; McLeod JF
J Clin Endocrinol Metab; 2000 Mar; 85(3):1081-6. PubMed ID: 10720043
[TBL] [Abstract][Full Text] [Related]
7. Nateglinide: a new rapid-acting insulinotropic agent.
Hanif W; Kumar S
Expert Opin Pharmacother; 2001 Jun; 2(6):1027-31. PubMed ID: 11585005
[TBL] [Abstract][Full Text] [Related]
8. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
9. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
Luzio SD; Anderson DM; Owens DR
J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
[TBL] [Abstract][Full Text] [Related]
10. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.
Walter YH; Spratt DI; Garreffa S; McLeod JF
Eur J Clin Pharmacol; 2000 May; 56(2):129-33. PubMed ID: 10877006
[TBL] [Abstract][Full Text] [Related]
11. Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoglycaemic agents, NN623 and A4166.
Kikuchi M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S151-5. PubMed ID: 8894500
[TBL] [Abstract][Full Text] [Related]
12. The mechanisms underlying the unique pharmacodynamics of nateglinide.
Hu S; Boettcher BR; Dunning BE
Diabetologia; 2003 Mar; 46 Suppl 1():M37-43. PubMed ID: 12652357
[TBL] [Abstract][Full Text] [Related]
13. A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris N; Voulgari C; Katsilambros N
Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes.
Juurinen L; Tiikkainen M; Saltevo J; Nikkilä K; Lanki H; Leppävuori E; Kock T; Teikari-Myyrä T; Kauppinen-Mäkelin R; Kotronen A; Yki-Järvinen H
Diabet Med; 2009 Apr; 26(4):409-15. PubMed ID: 19388972
[TBL] [Abstract][Full Text] [Related]
15. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin.
Hirschberg Y; Karara AH; Pietri AO; McLeod JF
Diabetes Care; 2000 Mar; 23(3):349-53. PubMed ID: 10868864
[TBL] [Abstract][Full Text] [Related]
16. [Nateglinide].
Notoya Y; Kikuchi M
Nihon Rinsho; 2002 Sep; 60 Suppl 9():371-5. PubMed ID: 12387020
[No Abstract] [Full Text] [Related]
17. [Clinical trial of AY4166].
Kikuchi M
Nihon Rinsho; 1997 Nov; 55 Suppl():164-70. PubMed ID: 9434462
[No Abstract] [Full Text] [Related]
18. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
Scheen AJ
Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
[TBL] [Abstract][Full Text] [Related]
19. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
Dashora UK; Sibal L; Ashwell SG; Home PD
Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
[TBL] [Abstract][Full Text] [Related]
20. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Schwarz SL; Gerich JE; Marcellari A; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Obes Metab; 2008 Aug; 10(8):652-60. PubMed ID: 17941876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]